Granules India Ltd.

NSE: GRANULES BSE: 532482 SECTOR: Pharmaceuticals & Drugs  85k   991   196

256.75
+12.35 (5.05%)
NSE: 24 Jun 03:58 PM

Price Summary

Today's High

₹ 258.1

Today's Low

₹ 241.7

52 Week High

₹ 404.8

52 Week Low

₹ 226.95

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

6367.55 Cr.

Enterprise Value

6974.94 Cr.

No. of Shares

24.8 Cr.

P/E

16.47

P/B

2.52

Face Value

₹ 1

Div. Yield

0.58 %

Book Value (TTM)

₹  102.04

CASH

241.23 Cr.

DEBT

848.62 Cr.

Promoter Holding

41.98 %

EPS (TTM)

₹  15.58

Sales Growth

35.72%

ROE

27.95 %

ROCE

26.49%

Profit Growth

24.48 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year35.72%
3 Year23.94%
5 Year18.75%

Profit Growth

1 Year24.48%
3 Year58.37%
5 Year35.55%

ROE%

1 Year27.95%
3 Year22.53%
5 Year19.86%

ROCE %

1 Year26.49%
3 Year20.24%
5 Year18.04%

Debt/Equity

0.3943

Price to Cash Flow

17

Interest Cover Ratio

31.8266712655475

CFO/PAT (5 Yr. Avg.)

0.909581106493234

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2022 41.98 6.92
Dec 2021 41.98 6.92
Sep 2021 42.04 6.92
Jun 2021 42.04 6.92
Mar 2021 42.04 8.64
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 58.3719032105051% for the Past 3 years.
  • The company has shown a good revenue growth of 23.9398411557353% for the Past 3 years.
  • Company has been maintaining healthy ROE of 22.5258282971301% over the past 3 years.
  • Company has been maintaining healthy ROCE of 20.2379931433479% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 31.8266712655475.
  • The Company has been maintaining an effective average operating margins of 20.6467401657508% in the last 5 years.
  • Company’s PEG ratio is 0.592923339320609.
  • The company has an efficient Cash Conversion Cycle of 39.5524854087237 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 4.22297581044264.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net Sales 781.55 732.12 703.69 889.78 912.85
Total Expenditure 558.64 582.08 610.28 697.74 706.88
Operating Profit 222.92 150.04 93.41 192.04 205.97
Other Income 3.06 7.36 4.28 4.79 4.28
Interest 5.75 5.38 4.01 2.96 4
Depreciation 30.51 31.5 31.86 31.13 31.68
Exceptional Items 0 0 0 0 0
Profit Before Tax 189.71 120.51 61.83 162.74 174.56
Tax 47.46 30.67 15.73 41.41 45.32
Profit After Tax 142.25 89.85 46.1 121.33 129.24
Adjusted EPS (Rs) 5.74 3.63 1.86 4.89 5.21

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 1349.48 1646.64 2098.43 2309.93 3134.98
Total Expenditure 1053.68 1353.12 1766.08 1815.79 2273.61
Operating Profit 295.8 293.53 332.35 494.14 861.37
Other Income 14.52 23.77 28.49 26.46 13.72
Interest 32.16 32.93 28.36 26.86 23.77
Depreciation 71.35 75.92 90.77 101.82 118.45
Exceptional Items 0 0 0 161.12 0
Profit Before Tax 206.8 208.45 241.71 553.03 732.87
Tax 63.98 69.29 79.87 108.96 180.09
Net Profit 142.83 139.16 161.84 444.07 552.78
Adjusted EPS (Rs.) 6.25 5.48 6.37 17.47 22.32

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 22.87 25.38 25.42 25.42 24.77
Total Reserves 861.49 1252.81 1397.81 1786.16 2137.85
Borrowings 124.24 433.13 478.78 420.92 341.14
Other N/C liabilities 71.28 70.52 79.51 66.22 50.74
Current liabilities 775.09 856.95 842.84 847.45 1128.33
Total Liabilities 1854.97 2638.8 2824.37 3146.18 3682.83
Assets
Net Block 605.58 660.15 699.95 926.88 985
Capital WIP 120.02 271.04 308.74 100.86 146.58
Intangible WIP 12.29 14.99 24.28 28.92 17.43
Investments 75.12 75.12 506.46 445.39 591.53
Loans & Advances 208.47 439 76.02 169.24 64.42
Other N/C Assets 0 0 0 0 0
Current Assets 833.5 1178.5 1208.91 1474.88 1877.87
Total Assets 1854.97 2638.8 2824.37 3146.18 3682.83
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 206.8 208.45 241.71 553.03 732.87
Adjustment 94.81 91.94 121.92 -53.91 153.72
Changes in Assets & Liabilities -52.64 -222.92 -49.97 115.3 -325.99
Tax Paid -58.83 -53.49 -86.8 -119.63 -185.94
Operating Cash Flow 190.14 23.98 226.85 494.79 374.66
Investing Cash Flow -299.2 -494.86 -242.91 -164.6 -232.74
Financing Cash Flow 36.23 528.75 -17.33 -212.29 -296.21
Net Cash Flow -72.83 57.87 -33.39 117.9 -154.29

Corporate Actions

Investors Details

PARTICULARS Mar 2021% Jun 2021% Sep 2021% Dec 2021% Mar 2022%
Promoters 42.04 42.04 42.04 41.98 41.98
c krishna prasad - - - - 28.41
krishna prasad chi... 34.84 34.84 34.80 34.80 -
tyche technologies... - - - - 10.65
chigurupati uma ... - - - - 3.90
chigurupati uma de... 3.82 3.82 3.81 3.81 -
tyche investments ... 1.47 1.47 1.47 1.47 -
chigurupati pragnya 0.76 0.76 0.76 0.76 -
pragnya chigurupa... - - - - 0.77
chigurupati priyan... 0.75 0.75 0.75 0.75 -
priyanka chigurup... - - - - 0.77
priyanka chigurupa... - - - - -
santhi sree ramana... 0.35 0.35 0.35 0.35 0.36
suseela devi chig... - - - - 0.07
suseela devi chigu... 0.03 0.03 0.03 0.03 -
nikhila reddy yada... 0.01 0.01 0.01 0.01 -
nikhila reddy yeda... - - - - -
yedaguri nikhila r... - - - - 0.01
nikhila reddy yed... - - - - -
PARTICULARS Mar 2021% Jun 2021% Sep 2021% Dec 2021% Mar 2022%
Investors 57.96 57.96 57.96 58.02 58.02
bnp paribas arbitr... - 3.33 - 3.47 -
bnp paribas arbitr... - - 3.33 - -
government pension... 3.01 3.01 3.10 3.20 2.52
life insurance cor... - - - - 1.07
fidelity funds-asi... - - - - -
fidelity funds - a... 1.55 1.81 1.86 1.78 -
mahima stocks priv... 1.49 1.47 1.48 1.40 -
fidelity funds - i... - - - 2.00 -
mondrian emerging ... - - - - 1.38
basava sankara rao... 1.21 1.21 1.21 1.21 1.43
basava sankararao ... - - - - -
basava shankar ra... - - - - -
morgan stanley (fr... - - - - 1.18
morgan stanley asi... - - - - -
fidelity asian val... - - - - -
alternative invest... 0.09 - 0.01 - -
qualified institut... - - - 0.18 -
qualified institui... 0.15 - - - -
iepf 0.10 0.10 0.10 0.10 -
i e p f - - - - 0.07
qualified institui... - - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Granules India informs about audio recording of conference call19 May 2022, 4:34PM Granules India - Quaterly Results18 May 2022, 4:23PM Granules India - Quaterly Results18 May 2022, 4:23PM Granules India - Quaterly Results18 May 2022, 4:23PM Granules India informs about analyst meet16 Apr 2022, 12:25PM Granules India informs about closure of trading window29 Mar 2022, 12:27PM Granules India informs about analyst meet23 Mar 2022, 12:03PM Granules India gets licences from MPP to market Nirmatrelvir, Ritonavir19 Mar 2022, 9:18AM Granules India’s foreign subsidiary clears US FDA audit15 Mar 2022, 12:48PM Granules India - Quaterly Results8 Feb 2022, 1:46PM Granules India - Quaterly Results8 Feb 2022, 1:46PM Granules India - Quaterly Results8 Feb 2022, 1:46PM Granules India’s arm gets ANDA approval for Bupropion Hydrochloride Extended-Release Tablets3 Feb 2022, 3:12PM Granules India informs about press release31 Jan 2022, 9:49AM Granules India’s arm concludes USFDA audit with three minor observations31 Jan 2022, 9:22AM Granules India’s arm gets ANDA approval for Potassium Chloride for Oral Solution28 Jan 2022, 3:59PM Granules India informs about press release30 Dec 2021, 12:09PM Granules India’s arm receives ANDA approval for Amphetamine Mixed Salts 30 Dec 2021, 10:45AM Granules India informs about press release28 Dec 2021, 10:57AM Granules India’s arm gets ANDA approval from USFDA for Prazosin Hydrochloride Capsules28 Dec 2021, 10:50AM Granules India informs about press release28 Dec 2021, 10:48AM Granules India informs about outcome of board meeting13 Dec 2021, 2:37PM Granules India informs about analyst meet 17 Nov 2021, 4:44PM Granules India’s arm gets USFDA approval for Dofetilide capsules 18 Oct 2021, 4:13PM Granules India informs about allotment of equity shares1 Oct 2021, 3:25PM Granules India of informs about closure of trading window29 Sep 2021, 11:59AM Granules India informs about analyst meet23 Sep 2021, 11:20AM Granules India informs about press release13 Sep 2021, 4:53PM Granules India recalling over 1.14 crore Naproxen Sodium tablets 13 Sep 2021, 10:42AM Granules India gets licence from DRDO to manufacture, market COVID-19 drug3 Sep 2021, 10:16AM Granules India gets marketing approval for Acetaminophen Extended-Release Tablets30 Aug 2021, 11:51AM Granules India informs about press release30 Aug 2021, 10:55AM Granules India reports 8% rise in Q1 consolidated net profit28 Jul 2021, 11:44AM Granules India’s arm clears audit by US health regulator 22 Jul 2021, 11:41AM Granules India informs about board meeting15 Jul 2021, 3:14PM Granules India informs about clarification12 Jul 2021, 9:33AM USFDA completes inspection at facility of Granules India’s arm28 Jun 2021, 9:25AM Granules India earmarks capex of Rs 1,000 crore till FY2417 May 2021, 9:07AM Granules India pledges to provide Telangana government 16 crore Paracetamol-500 mg tablets13 May 2021, 11:27AM Granules India informs about presentation to analysts11 May 2021, 4:40PM Granules India reports 38% rise in Q4 consolidated net profit11 May 2021, 4:04PM Granules India informs about board meeting3 May 2021, 10:37AM Granules India informs about analyst meet15 Mar 2021, 3:37PM Granules India gets approval for Acetaminophen, Aspirin and Caffeine Tablets 24 Feb 2021, 12:26PM Granules India gets approval for Potassium Chloride ER Capsules USP17 Feb 2021, 2:40PM USFDA approves ANDA filed by Granules India’s arm for Potassium Chloride Oral Solution1 Feb 2021, 10:45AM Granules India informs about earnings conference call18 Jan 2021, 10:58AM Granules India board to approve un-audited financial results13 Jan 2021, 1:16PM Granules India gets USFDA’s approval for Metformin Hydrochloride ER Tablets 13 Jan 2021, 12:42PM Granules India’s arm gets USFDA nod for generic Penicillamine capsules4 Dec 2020, 9:29AM

Granules India Stock Price Analysis and Quick Research Report. Is Granules India an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Granules India and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 374.6584 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Granules India has a Debt to Equity ratio of 0.3943 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Granules India , the EPS growth was 27.7848391159968 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Granules India has OPM of 27.4761446826623 % which is a good sign for profitability.
     
  • ROE: Granules India have a healthy ROE of 27.9527378983839 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Granules India

X